Henlix (Taiwan) is a biopharmaceutical company specialized in innovative antibody-based oncology therapeutics. Henlix is led by experienced management with a proven track record in advancing multiple biologics through approval. Henlix has established state-of-the-art antibody platforms enabling efficient antibody discovery and development. Henlix has constructed a robust and synergistic product line that addresses a wide-array of key unmet medical needs.